Profile data is unavailable for this security.
About the company
Chromocell Therapeutics Corporation is a clinical-stage biotech company, which is focused on developing and commercializing therapeutics to alleviate pain. The Company's clinical focus is to selectively target the sodium ion-channel, NaV1.7, as well as other receptors in the NaV family. Its lead compound, CC8464, is designed to address both the underlying condition and mitigate the burning pain symptoms, which erythromelalgia (EM) patients experience by blocking the NaV1.7 sodium channel. CC8464 has completed Phase I study. A total of approximately 207 healthy subjects have been dosed in four Phase I studies (CC8464-1001, CC8464-1002, CC8464-1003, and 1807-CL-0102) with study treatment.
- Revenue in USD (TTM)0.00
- Net income in USD-8.98m
- Incorporated2021
- Employees4.00
- LocationChromocell Therapeutics Corp685 Us Highway OneNORTH BRUNSWICK 08902United StatesUSA
- Phone+1 (917) 644-6313
- Fax+1 (302) 658-3694
- Websitehttps://chromocell.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Alaunos Therapeutics Inc | 7.00k | -19.13m | 4.42m | 1.00 | -- | 1.17 | -- | 631.35 | -11.95 | -11.95 | 0.0044 | 2.36 | 0.0004 | -- | 1.75 | 7,000.00 | -117.34 | -74.83 | -143.58 | -89.57 | -- | -- | -273,271.40 | -10,508.06 | -- | -- | 0.00 | -- | -99.83 | -49.08 | 6.86 | -- | -15.56 | -- |
Palisade Bio Inc | 0.00 | -14.17m | 4.45m | 9.00 | -- | 0.3653 | -- | -- | -20.07 | -20.07 | 0.00 | 10.30 | 0.00 | -- | -- | 0.00 | -90.97 | -132.36 | -109.07 | -165.45 | -- | -- | -- | -27,892.32 | -- | -972.73 | 0.0339 | -- | -- | -0.7814 | 13.74 | -- | 18.53 | -- |
Oncternal Therapeutics Inc | 1.85m | -35.97m | 4.53m | 27.00 | -- | 0.2875 | -- | 2.45 | -12.19 | -12.19 | 0.6254 | 5.32 | 0.0495 | -- | -- | 68,370.37 | -96.40 | -49.40 | -116.52 | -54.51 | -- | -- | -1,948.70 | -1,342.98 | -- | -- | 0.00 | -- | -47.32 | -- | 10.62 | -- | -- | -- |
Qualigen Therapeutics Inc | 0.00 | -9.27m | 4.57m | 4.00 | -- | -- | -- | -- | -1.66 | -1.75 | 0.00 | -0.445 | 0.00 | -- | -- | 0.00 | -134.64 | -- | -- | -- | -- | -- | -- | -- | -- | -9.64 | -- | -- | -- | -- | 10.22 | -- | -- | -- |
CNS Pharmaceuticals Inc | 0.00 | -15.97m | 4.60m | 3.00 | -- | -- | -- | -- | -134.04 | -134.04 | 0.00 | -2.97 | 0.00 | -- | -- | 0.00 | -358.12 | -132.47 | -- | -185.75 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -23.42 | -- | -- | -- |
Pasithea Therapeutics Corp | 0.00 | -16.37m | 4.61m | 8.00 | -- | 0.2853 | -- | -- | -14.98 | -14.99 | 0.00 | 15.49 | 0.00 | -- | -- | 0.00 | -58.66 | -- | -62.74 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -32.23 | -- | -- | -- |
Chromocell Therapeutics Corp | 0.00 | -8.98m | 4.90m | 4.00 | -- | 4.34 | -- | -- | -1.66 | -1.66 | 0.00 | 0.196 | 0.00 | -- | -- | 0.00 | -440.01 | -- | -- | -- | -- | -- | -- | -- | -- | -7.20 | 0.00 | -- | -- | -- | -200.20 | -- | -- | -- |
ProtoKinetix, Inc. | 0.00 | -369.97k | 4.91m | 0.00 | -- | 12.10 | -- | -- | -0.0011 | -0.0011 | 0.00 | 0.0012 | 0.00 | -- | -- | -- | -78.67 | -696.88 | -85.20 | -785.51 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 78.22 | -- | 10.78 | -- |
Clearmind Medicine Inc | 0.00 | -8.44m | 4.91m | -- | -- | 1.39 | -- | -- | -12.73 | -12.73 | 0.00 | 0.8728 | 0.00 | -- | -- | -- | -133.31 | -218.20 | -266.82 | -488.96 | -- | -- | -- | -- | -- | -2.60 | 0.0172 | -- | -- | -- | -25.03 | -- | -- | -- |
Cingulate Inc | 0.00 | -19.10m | 4.94m | 13.00 | -- | 1.32 | -- | -- | -141.60 | -141.60 | 0.00 | 3.95 | 0.00 | -- | -- | 0.00 | -368.85 | -- | -- | -- | -- | -- | -- | -- | -- | -47.38 | 0.0042 | -- | -- | -- | -33.14 | -- | -- | -- |
Biostax Corp | 0.00 | -1.51m | 5.02m | -- | -- | -- | -- | -- | -0.0181 | -0.0181 | 0.00 | -0.0633 | 0.00 | -- | -- | -- | -395.44 | -81.51 | -- | -- | -- | -- | -- | -- | -- | -4.04 | -- | -- | -- | -- | 53.32 | -- | -- | -- |
Windtree Therapeutics Inc | 0.00 | -11.38m | 5.04m | 15.00 | -- | 0.5303 | -- | -- | -0.7463 | -0.7463 | 0.00 | 17.65 | 0.00 | -- | -- | 0.00 | -32.86 | -44.51 | -40.15 | -48.38 | -- | -- | -- | -94,533.34 | -- | -- | 0.1612 | -- | -- | -- | 48.25 | -- | -- | -- |
Weed Inc | 0.00 | 57.30k | 5.31m | 2.00 | 84.31 | 706.08 | 61.40 | -- | 0.0005 | 0.0005 | 0.00 | 0.00006 | 0.00 | -- | -- | 0.00 | 6.00 | -385.93 | -- | -822.37 | -- | -- | -- | -- | -- | -46.08 | 0.944 | -- | -- | -- | 97.93 | -- | -59.13 | -- |
Burzynski Research Institute Inc | 0.00 | -1.42m | 5.40m | 2.00 | -- | -- | -- | -- | -0.0108 | -0.0108 | 0.00 | -0.001 | 0.00 | -- | -- | -- | -153,444.30 | -15,304.89 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -45.74 | -- | -- | -- |
Data as of Sep 21 2024. Currency figures normalised to Chromocell Therapeutics Corp's reporting currency: US Dollar USD
Holder | Shares | % Held |
---|---|---|
3i Management LLCas of 21 Feb 2024 | 318.82k | 5.53% |
Anson Funds Management LPas of 30 Jun 2024 | 201.03k | 3.49% |
Citadel Securities LLCas of 30 Jun 2024 | 18.71k | 0.33% |
UBS Securities LLCas of 30 Jun 2024 | 186.00 | 0.00% |
Bank of America, NA (Private Banking)as of 30 Jun 2024 | 9.00 | 0.00% |
Tower Research Capital LLCas of 30 Jun 2024 | 6.00 | 0.00% |
More ▼
Data from 30 Jun 2024 - 23 Jul 2024Source: FactSet Research Systems Inc.